Abstract: A pull across screen assembly has a flexible screen member (e.g. flymesh) wound about a vertical rod positioned at one side of the opening. A line member arrangement is attached to the front of the screen member and part of the line member winds about a tapered drum which is positioned on top of rod and which rotates with rotation of the rod. The arrangement allows the screen member to be tensioned and also to be balanced as it is pulled across the opening.

Abstract: A flexible screen material can be cut out of square, or part of the screen frame can be formed out of square such that when the screen is fitted to the screen frame, there is less sagging.

Abstract: A flexible screen material can be cut out of square, or part of the screen frame can be formed out of square such that when the screen is fitted to the screen frame, there is less sagging.

Abstract: A flexible screen material can be cut out of square, or part of the screen frame can be formed out of square such that when the screen is fitted to the screen frame, there is less sagging.

Abstract: A flexible screen material can be cut out of square, or part of the screen frame can be formed out of square such that when the screen is fitted to the screen frame, there is less sagging.

Abstract: Disclosed herein are compounds represented by Structural Formula (I) and (I-A): Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply “CRTH2” for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.

Abstract: The present invention is directed to the compound of formula (II), or a solvate thereof, or crystalline forms thereof; to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (II), including crystalline forms thereof, and a pharmaceutically acceptable carrier; and to the use of a compound of formula (II), or crystalline forms thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting IKK-2, and methods related thereto.

Abstract: The present invention is directed to the Tartrate, Mono-Hydrochloride, Malonate and p-Toluenesulfonate Salts of the compound of formula (I), or solvates thereof, or crystalline forms thereof; to a pharmaceutical composition comprising a pharmaceutically effective amount of the Salts, including crystalline forms thereof, and a pharmaceutically acceptable carrier; and to the use of the Salts, including crystalline forms thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting IKK-2, and methods related thereto.

Abstract: Disclosed herein are compounds represented by Structural Formula (I) and (I-A): Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply “CRTH2” for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.

Abstract: A pull across screen assembly has a flexible screen member (e.g. flymesh) wound about a vertical rod positioned at one side of the opening. A line member arrangement is attached to the front of the screen member and part of the line member winds about a tapered drum which is positioned on top of rod and which rotates with rotation of the rod. The arrangement allows the screen member to be tensioned and also to be balanced as it is pulled across the opening.

Abstract: Selected nickel complexes of the anions of certain 2-aminotropones are olefin polymerization catalysts. Novel 2-aminotropones and their nickel complexes are also disclosed together with methods of making these 2-aminotropones.

Abstract: The present invention is directed to an arylation of a nuclophile by reacting the nucleophile with a substrate aromatic compound ArX in the presence of a copper catalyst, a base and water, wherein Ar is aryl, heteroaryl or alkenyl, X is halo, sulfonate or phosphonate, the base comprises an alkaline earth carbonate, bicarbonate, hydroxide or phosphate, and the copper catalyst comprises a copper atom or ion and a ligand.

Abstract: Disclosed herein are compounds represented by Structural Formula (I) and (I-A): Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply “CRTH2” for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.

Abstract: Selected nickel complexes of the anions of certain 2-aminotropones are olefin polymerization catalysts. Novel 2-aminotropones and their nickel complexes are also disclosed together with methods of making these 2-aminotropones.

Abstract: A method for making an indole compound includes transition metal-catalyzed arylation of a hydrazone to form an aryl hydrazone, hydrolysis of the aryl hydrazone to form an aryl hydrazine, and acid catalyzed cyclization of the aryl hydrazine to form the indole compound.

Abstract: Selected nickel complexes of the anions of certain 2-aminotropones are olefin polymerization catalysts. Novel 2-aminotropones and their nickel complexes are also disclosed together with methods of making these 2-aminotropones. Suitable complexes have the following structure: wherein: R2 is hydrocarbyl or substituted hydrocarbyl, provided that R2 is attached to said nitrogen atom in (I) by an atom that has at least 2 other atoms that are not hydrogen attached to it; and R3, R4, R5, R6 and R7 are each independently hydrogen, hydrocarbyl, substituted hydrocarbyl or a functional group, provided that any two of R3, R4, R5, R6 and R7 vicinal to one another may form a ring; L1 is a monodentate monoanionic ligand and L2 is a monodentate neutral ligand or an empty coordination site, or L1 and L2 taken together are a monoanionic bidentate ligand.

Abstract: Oriented film is provided formed from a blend of a homogeneous copolymer resin derived from units of acrylonitrile (70 to 93% molar) and at least one aromatic olefine (30 to 7% molar) with a graft copolymer having a diene rubber substrate and a superstrate which is a homogeneous copolymer derived from units of acrylonitrile (70 to 93% molar) and at least one aromatic olefine (30 to 7% molar) the blend containing 5 to 15% by weight of rubber and the refractive indices of the substrate and superstrate being within 0.005 of that of the homogeneous copolymer resin, the film having a Gardner haze of less than 10% having been drawn in at least one direction to a ratio of at least 1.7:1 at a temperature of between 105.degree. and 155.degree. C.